Hologic (HOLX) Receives Price Target

Hologic (HOLX) : The consensus price target for Hologic (HOLX) is $42.39 for the short term with a standard deviation of $2.47. The most optimist securities analyst among the 13 who monitor the stock believes that the stock can reach $46, however, the pessimist price target for the company is $39.

Hologic (HOLX) : 15 analysts are covering Hologic (HOLX) and their average rating on the stock is 2.07, which is read as a Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 8 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, Major Brokerage house, Evercore ISI Group upgrades its ratings on Hologic (NASDAQ:HOLX). According to the latest information available, the shares are now rated Buy by the analysts at the agency. Previously, the analysts had a Hold rating on the shares. The rating by the firm was issued on July 28, 2016.

Hologic (NASDAQ:HOLX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $38.39 and $38.12 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $38.58. The buying momentum continued till the end and the stock did not give up its gains. It closed at $38.46, notching a gain of 0.10% for the day. The total traded volume was 1,699,124 . The stock had closed at $38.42 on the previous day.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.